AstraZeneca PLC (AZN) Total Return:25.21%(TTM)
Over the latest trailing 12-month period, AstraZeneca PLC (AZN)'s total return cagr is +25.21%. The comparable SPY value is +24.09%. Year-to-date total return is +4.97%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in AZN
$228,864
(22.9x return)
Invested on Jun 12, 1996
Growth of $10,000 in SPY (S&P 500)
$184,570
(18.5x return)
Invested on Jun 12, 1996
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
+5.0%
1-Year Total Return
+25.2%
Current Dividend Yield
1.76%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | +23.0% | +25.2% | +2.2% |
| 3 Years | +6.9% | +9.1% | +2.2% |
| 5 Years | +9.1% | +11.5% | +2.4% |
| 10 Years | +12.7% | +16.0% | +3.3% |
| 15 Years | +9.0% | +13.0% | +4.0% |
| 20 Years | +6.3% | +10.5% | +4.2% |
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot